The innate immune system of mammals is a key defense mechanism against invading foreign pathogens. Innate immune stimulants may have applications as vaccine adjuvants as well as in the treatment of cancer and some viral diseases, and clinical studies have been performed using agonists of Toll-like receptors (TLRs) 7, 8, and 9. The high-throughput screens for such agonists have typically relied on the overexpression of a single TLR gene in an immortalized cell line and are inherently artificial systems that are restricted to the identification of agonists for a single receptor. The authors describe 2 assays for the identification of immunostimulants that employ primary human leukocytes cocultured with hepatitis C virus (HCV) replicon-expressing cells. In these assays, stimulation of innate immune pathways in leukocytes induces interferon (IFN) expression, which acts to inhibit HCV replication, providing a high-throughput and low-cost readout for leukocyte activation. These assays are highly sensitive and provide a physiologically relevant system for the identification of a broad range of immunostimulant agents. (Journal of Biomolecular Screening 2009:723-730) 
INTRODUCTION
T he innate immune system of mammals is a key defense mechanism against invading foreign pathogens. A number of receptors for nonself molecules exist within mammalian cells, including members of the Toll-like receptor (TLR) family and the intracellular RNA helicases RIG-I and MDA5 (reviewed in Gantier and Williams 1 ). The TLRs are a family of pattern recognition receptors that detect nonself molecules such as the bacterial cell wall component lipopolysaccharide (LPS), bacterial flagellin, lipoprotein, peptidoglycan, and microbial nucleic acids. 2 Activation of TLRs leads to the transcription of genes encoding cytokines, chemokines, and other costimulatory molecules capable of activating both the innate and adaptive immune systems.
Of the 10 TLRs identified to date, TLR7, TLR8, and TLR9 are the 3 that have been primarily targeted for the design of immunostimulant therapeutics. These 3 TLRs, along with TLR3, are all receptors for microbial nucleic acids, 3, 4 and their activation results in the production of interferons (IFNs). 5 TLR3 is expressed by natural killer (NK) cells, fibroblasts, and epithelial cells 6 and is activated by double-stranded RNA. 3 TLR7 and TLR8 are both activated by single-stranded (and possibly double-stranded) RNA. 7, 8 TLR7 is abundantly expressed in plasmacytoid dendritic cells (pDCs) and, to a lesser extent, in B cells and monocytes, whereas TLR8 is expressed primarily in monocytes. 9 TLR9 is activated by microbial CpG DNA and is expressed in pDCs and B cells. 4, 9 TLR agonists may have applications as vaccine adjuvants as well as in the treatment of cancer and some viral diseases. Several different classes of TLR agonists have been developed to date, including the imidazoquinoline TLR7/8 agonists (resiquimod a.k.a. R-848, imiquimod, gardiquimod, CL075, CL087, and CL097), the guanosine-like TLR7 agonists (isatoribine and loxoribine), and the CpG phosphorothioate DNA oligonucleotides (CPG 10101, IMO-2055, and IMO-2125). Members of each of the above listed classes have been tested clinically, and a number of clinical trials are ongoing.
The majority of the TLR agonists listed above were identified in animal models, before the discovery of their cognate receptor(s). The relatively recent identification of a number of innate immune receptor proteins has spurred reinvestigation of innate immune stimulatory agents. The most commonly used high-throughput screening (HTS) technique for identification of TLR agonists is measurement of NFκB activity in a cell line (typically HEK293) overexpressing a specific TLR gene. 10, 11 However, this technique is relatively insensitive; is prone to false positives from non-TLR-specific NFκB activation; is limited to the identification of immunostimulants that bind to a single, specific TLR; and has been shown not to fully recapitulate the in vivo responsiveness of TLRs. 12 Other assay systems for the measurement of TLR activation have been reported, 11, 13 although these assays have been employed primarily for cell biology or mechanism of action studies and are not well suited for screening or structure-activity relationship applications. Recently, a novel approach for measurement of TLR activation was reported, which used suppression of a hepatitis C virus (HCV) replicon as a surrogate marker for IFN production by primary leukocytes treated with TLR agonists. 5 In the present study, we have adapted and investigated this assay for screening. Moreover, by isolating the plasmacytoid dendritic cell fraction of the leukocytes, we have developed an assay with improved sensitivity and robustness. Both of these assays are sensitive and capable of identifying a broad range of immunostimulants of relatively high physiological relevance (because of the use of primary cells).
MATERIALS AND METHODS

Cell culture
Human hepatoma cells (Huh7) containing a stable pFK-I389/NS3-3′/5.1-based, luciferase-expressing HCV replicon (Huh7-Luc) 14 were maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) containing 10% fetal calf serum (FCS; Sigma-Aldrich, St. Louis, MO) and 750 µg/mL G418 (Invitrogen) at 37 °C in a 5% CO 2 incubator.
Peripheral blood mononuclear cell isolation
Buffy coats were obtained from the Australian Red Cross Blood Service. Then, 50 mL of buffy coat was diluted 1:3 with DM-L wash buffer (phosphate-buffered saline [PBS] + 2% FCS). This mixture was split into 6 separate 25-mL aliquots and each 25 mL of diluted cells layered over 15 mL of RosetteSep DM-L (Stemcell Technologies, Vancouver, Canada) solution. Following centrifugation for 20 min at 1200 g, erythrocytes were discarded and the mononuclear band washed with 40 mL DM-L wash buffer. Cells were pooled in 10 mL DM-L wash buffer prior to addition of 25 mL ammonium chloride solution (Stemcell Technologies). Following 5 min incubation on ice, the cells were centrifuged at 300 g for 5 min and resuspended in 50 mL DM-L wash buffer. Cells were either used immediately or frozen in 10% DMSO/90% FCS and stored in liquid N 2 until required. The experiments described used cryopreserved cells unless noted otherwise in the text.
Plasmacytoid dendritic cell purification
pDCs were purified by negative selection using a plasmacytoid dendritic cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Briefly, fresh peripheral blood mononuclear cells (PBMCs) were resuspended in MACS buffer (PBS [pH 7.2], 0.5% bovine serum albumin [BSA], 2 mM EDTA) and 100 µL PDC biotin antibody cocktail added per 10 8 cells. Following incubation on ice for 10 min, the cells were washed twice with 10 mL MACS buffer per 10 8 cells. Cells were incubated with 100 µL antibiotin microbeads for 15 min on ice and washed in MACS buffer prior to being loaded on an LS column (Miltenyi Biotec). The unlabeled fraction containing the enriched pDC fraction was collected and cells stained with CD303-FITC (Miltenyi Biotec) and CD45-PerCP (Becton Dickinson, Mountain View, CA). Analysis of pDC purity was performed by flow cytometry using a FACSCalibur flow cytometer (Becton Dickinson).
Stimulation of TLR signaling in PBMCs and pDCs
The following small-molecule TLR ligands were dissolved in DMSO and stored at -20 °C until use: resiquimod, imiquimod, and loxoribine (all from Alexis Biochemicals, Lausen, Switzerland) and CL075, CL087, CL097, and gardiquimod (all from Invivogen, San Diego, CA). Stock solutions of β-form DNA complexed with LyoVec, ODN2216, and ODN2336; ssRNA40 complexed with LyoVec; ssPolyU complexed with LyoVec (all from Invivogen); and Poly(I:C) (Sigma-Aldrich) were made in 10% FCS and stored at -80 °C until use. Sendai virus (Cantell strain) was purchased from Charles River Laboratories (Wilmington, MA). Unless otherwise indicated, cells were treated with 100 U/mL IFN-α. For IFN-α neutralizing experiments, 1 µg/mL of IFN-α2 (R&D Systems, Minneapolis, MN) was incubated with pDCs and Huh7-Luc cells for 48 h.
For coculture experiments, Huh7-Luc cells were seeded at 7500 cells/well in 80 µL antibiotic-free media (10% FCS-DMEM) in white 96-well plates (Greiner Bio-one, Frickenhausen, Germany). Media were removed 24 h postseeding, and either PBMCs or pDCs in 90 µL 10% FCS-RPMI were added to each well along with TLR agonist (final volume of 100 µL/well; maximum 1% DMSO per well). After addition of stimuli, the plates were incubated at 37 °C in a 5% CO 2 incubator for 48 h. PBMCs or pDCs were subsequently removed and proliferation of Huh7 or Huh7-Luc cells determined using the CellTiter-Blue (CTB) assay (Promega, Madison, WI). Following measurement of fluorescence (Fluostar Optima plate reader, BMG Labtech, Offenburg, Germany), the CTB reagent was removed and cells lysed with 30 µL 1× Passive Lysis Buffer (Promega) at room temperature for 10 min. Luminescence was measured every 0.5 s for 5 s using automatic substrate injection (luciferase assay system, Promega) and average luminescence calculated for each well. An alternative assay system was used according to methods described by Thomas et al. 5 Briefly, 10 µL supernatant from 100,000 PBMCs in 100 µL in 10% FCS-RPMI that had been treated for 24 h with stimulus was transferred to Huh7-Luc cells (10,000 cells/well) plated in 96-well plates and luminescence measured 48 hours later.
Plasmids and transfection
An interferon-stimulated response element (ISRE) plasmid (pISRE-TA-Luc) containing 5 tandem ISRE sequences upstream of a gene encoding firefly luciferase was purchased from Clontech (Mountain View, CA). To control for transfection variability, the pGL4.73 plasmid (Promega) expressing Renilla luciferase was cotransfected. For transfection, Huh7 cells were seeded at 6000 cells/well in 80 µL antibiotic-free 10% FCS-DMEM in 96-well plates. Then, 24 h later, 200 ng pISRE-TA-Luc and 1 ng pGL4.73 were complexed with Lipofectamine2000 (Invitrogen) and added to Huh7-Luc cells. Cells were treated with IFN-α or TLR agonist 24 h posttransfection, and luciferase expression was measured 48 h later using the Dual Luciferase Reagent (Promega). To account for transfection effects, we normalized the average firefly value (0.5-s measurements; 30 s total read/well) to the average Renilla value (0.5-s measurements; 30 s total read/well).
RESULTS AND DISCUSSION
Characterization of PBMC and pDC responses to TLR agonists
Due to the limitations of existing assay systems for the identification of immunostimulants, we sought to develop a cell-based assay capable of detecting a broad range of immunostimulant molecules. PBMCs have been shown to express all 10 TLRs and respond to a wide variety of TLR and non-TLR immunostimulants. 5, 9 As such, PBMCs are an ideal target cell for assaying immunostimulants. As a readout for innate immune stimulation of PBMCs, we chose to follow Thomas and coworkers 5 and use a Huh7-based cell line containing a luciferase-expressing HCV replicon (Huh7-Luc). Treatment of this cell line with IFN strongly inhibits HCV replication and consequently luciferase expression.
Previous work using Huh7-Luc cells as a surrogate marker of IFN production involved the transfer of supernatant from PBMC cultures to Huh7-luc cells. 5 An alternative technique, which minimizes cell manipulation steps, is to coculture PBMCs with Huh7-Luc cells and immunostimulants rather than transferring supernatant from PBMC cultures to Huh7-Luc cultures. We investigated the applicability of both of these techniques to screening experiments. Compared to supernatant transfer, coculture led to a slightly increased background signal, but this was more than compensated for by increased sensitivity to TLR7/8 agonists, particularly imiquimod, which demonstrated no activity under supernatant transfer conditions in our hands (data not shown). Z factors (calculated using 32 replicates of 5 µM resiquimod compared to 0.5% DMSO) for the supernatant transfer and coculture techniques were 0.15 and 0.24, respectively, indicating that both assays were workable. We found that cryopreservation did not affect the responsiveness of PBMCs to TLR7/8 agonists (data not shown).
Because the majority of IFNα produced by PBMCs in response to TLR7 agonists is thought to be derived from pDCs, we examined whether the use of purified pDCs might improve the sensitivity of the coculture assay system. Screening applications would practically require that pDCs be frozen without loss of function. Although PBMCs have been relatively well characterized, 5 the effects of cryopreservation and donor variation on the response of pDCs to TLR agonists are not known. We performed a direct comparison between fresh and recovered cryopreserved pDCs. When plated at a density of 500 cells/well, there was no decrease in the ability of cryopreserved pDCs to respond to resiquimod and imiquimod (data not shown), making cryopreservation of pDCs a viable option for screening. Donor variation in pDCs, on the other hand, could potentially be ameliorated by producing mixed bulk batches of pDCs prior to use for screening. However, such an approach is potentially confounded by the possibility of a mixed leukocyte reaction (MLR), in which alloreactive T cells from the different donors initiate a spontaneous immune response, independent of TLR activation. To test for any effect of an MLR on the assay readout, cryopreserved cells from each of the 3 pDC purifications performed were recovered and mixed prior to performing the pDC coculture assay. No significant suppression of HCV replication occurred in the absence of TLR7 agonists in any of the mixed pools of pDCs ( Fig. 1A) . Therefore, MLR either did not take place or did not result in IFN production, demonstrating the feasibility of the mixing pDCs from different isolations for use in coculture assays. A corollary of this experiment was that by mixing pDCs from different isolations, 7 different fractions of cells were produced with different CD303+ purities. The responsiveness of the pDCs differed between the different donors, particularly for the weak agonist loxoribine. This appeared to correlate with the purity of the preparation with the preparations from donors 1 and 2 having an 18.6% and 62.3% purity, respectively. Indeed, by comparing CD303 positivity with replicon suppression in response to imiquimod, we evaluated the impact of CD303 purity on response to TLR7 agonists ( Fig. 1B) and found a clear, positive correlation between CD303 positivity and replicon inhibition. Therefore, CD303 purity appears to account for the majority of donor variability. As has been described for assays using PBMCs, 5 we found that an IFNα-2 neutralizing antibody significantly inhibited pDCmediated replicon inhibition (Fig. 1C) , confirming that the replicon inhibition observed was at least partially due to IFNα-2.
To further characterize the pDC coculture screen, we generated a complete dose-response curve for TLR7/8 agonists using pDCs at densities of 25, 50, 100, or 200 CD303+ cells/100 µL. Activity was detected for imiquimod ( Fig. 2) and resiquimod (data not shown) with some dependence on pDC cell number observed. To determine an optimal cell density, we calculated z factors based on 24 replicates of each density of 25, 50, and 100 CD303+ cells/100 µL treated with 5 µM resiquimod. Twenty-five CD303+ cells/100 µL gave a z factor of less than 0.49, whereas 50 and 100 CD303+ cells/µL both gave z factors of 0.68 and 0.66, indicating no clear distinction in assay performance between these 2 cell densities. Thus, 50 CD303+ cells/100 µL appear to be sufficient for maximal assay performance and are a suitable density for further screening applications. Importantly, the observed EC 50 values for resiquimod and imiquimod in the pDC assay (<78 nM and 1.7 µM, respectively) were substantially lower than for the PBMC assay (239 nM and >10 µM, respectively). This assay is therefore more sensitive than any other published TLR7 screening assay.
Responsiveness of coculture assays to nucleic acid immunostimulants
Several classes of small-molecule TLR7/8 agonists are known. The development of small-molecule agonists of other innate immune nucleic acid receptors (TLR3, TLR9, RIG-I, MDA5, etc.) may also be possible, but to the best of our knowledge, none have been identified to date. Human PBMCs are a heterologous mixture of leukocytes, which between them express the full gamut of TLR genes. 9 Accordingly, when tested for responsiveness using a range of nucleic acid immunostimulants, cryopreserved PBMCs recovered in RPMI media demonstrated HCV suppression in response to TLR3 (PolyI:C), TLR 7/8 (resiquimod, ssRNA40, ssPolyU), and TLR9 (ODN2216, ODN2336) agonists (Fig. 3) . The PBMC coculture system also demonstrated responsiveness to transfected β-form DNA, which induces IFN expression through an as yet undefined IRF3-, TBK1-, and IKKε-dependent (but TLR-, RIG-I-, and MDA5-independent) process. pDCs typically comprise less than 1% of PBMCs and express only TLR1, TLR7, TLR9, and TLR10. 9 When tested with the panel of nucleic acid immunostimulants, the pDC coculture system demonstrated HCV suppression in response to both TLR7 (resiquimod, ssPolyU) and both TLR9 (ODN2216, ODN2336) agonists but not in response to the TLR3 (PolyI:C) or TLR8 (ssRNA40-the response to which may have been confounded by a screening artifact; see below) agonists or β-form DNA. However, it should be noted that activation of TLR8 in PBMCs results in strong induction of TNFα as well as IFN, which is likely to induce unwanted inflammatory effects in a therapeutic setting. 5 Thus, the pDC assay system provides a more sensitive and more robust (in terms of z factor) assay than the PBMC assay system, whereas the PBMC assay system is capable of detecting a broader range of immunostimulatory molecules, with the caveat that some of these may be intrinsically proinflammatory. As such, we consider these assays to be complementary.
Curiously, treatment of Huh7-Luc cells with ssRNA40 or Sendai virus in the absence of cocultured leukocytes resulted in a significant increase in luciferase signal, most likely indicating an increase in HCV replication. ssRNA40 is a 20-mer fully phosphorothioate single-stranded RNA molecule. ssRNA40 is composed of a GU-rich sequence derived from the HIV long terminal repeat region, and it has been shown to be a selective agonist for human TLR8. 12 However, treatment of Huh7-Luc cells with another TLR8-selective ligand, CL075, did not increase the luciferase signal (data not shown), indicating that the apparent increase in HCV replication induced by ssRNA40 was not due to TLR8 activity. Nonphosphorothioate PolyU RNA also appeared to cause a dose-dependent increase in luciferase signal in Huh7-Luc cells, although this effect was modest in comparison to that observed for ssRNA40 and Sendai virus. This apparent increase in HCV replication following transfection with RNA may result from competitive antagonism of intracellular antiviral RNA receptors (PKR, RIG-I, MDA5, etc.), but further studies are needed to investigate this hypothesis.
Responsiveness of coculture assays to a range of TLR7/TLR8 agonists
To characterize the responsiveness of the pDC and PBMC coculture assays to TLR7/8 agonists, we extended the range of agonists tested. The TLR7 agonist gardiquimod and TLR7/8 agonist CL097 were tested alongside resiquimod and imiquimod for activation of IFN production from pDC cells at a density of 50 CD303+ cells/100 µL (Fig. 4) . Each of these compounds elicited suppression of HCV replication, with EC 50 values in the nanomolar range for CL097 and resiquimod and the low micromolar range for gardiquimod. Imiquimod resulted in modest suppression of HCV replication using pDCs (EC 50 1.7 µM) and low suppression using PBMCs (EC 50 >10 µM).
A possible source of false-positives in these coculture screening systems are agents that are direct inhibitors of HCV replication or that are cytotoxic to the reporter cells. These limitations can be addressed in 2 ways: (1) directly measuring cytotoxicity (by CTB or other MTS/MTT-related assay) can be performed prior to the luciferase assay and (2) employing counterscreens of Huh7-Luc cells in the absence of leukocytes. The former strategy excludes only cytotoxic agents from the analysis but has the advantage that it can be performed in parallel to the luciferase read and thus requires a minimum of additional effort. The second approach excludes both cytotoxic and directly HCV inhibitory agents but requires an entire parallel screen. Although not always reported, we performed both of the above-mentioned counterscreens in parallel with every screening experiment discussed in the present study, demonstrating in each case the specificity of the response to each of the immunostimulants tested. It should be noted, however, that for screening applications, such assays are required only for any hits derived from a primary screen and so would have only a very modest effect on throughput.
Conclusions
Although drug screening is often limited to validated protein targets, it is arguably best applied to more complex and more physiologically relevant systems. Immune activation (in which modulation of seemingly validated targets can lead to unforseen consequences) exemplifies the sort of complex biological system that may be more accurately modeled by cell-based screens. Screens using immortalized cell lines are clearly of practical use in some circumstances. However, in the case of immune activation, the responses of cell lines are often not indicative of the responses of primary cells, and as such, they may constitute a poor model system. The response of myeloid cell lines to innate immune stimulation is a case in point, and although there are a number of immortalized myeloid cell lines that do respond to at least some forms of innate immune stimulation, the response is qualitatively different when compared to that of primary leukocytes (our unpublished observations). By using primary cells, the 2 screening systems described in the present study provide a physiologically relevant model system for the identification of a broad range of innate immune stimulants.
In the present study, we have developed 2 highly sensitive primary cell assays for the identification and characterization of immunostimulants. Of the 2 assays, the pDC/Huh7-luc coculture system is more sensitive, but the PBMC/Huh7-Luc coculture system is capable of detecting immunostimulants acting through a broader range of mechanisms. Thus, these assays are complementary and will be useful to confirm and characterize immunostimulatory molecules identified in primary screens. The availability of primary leukocyte-based assays may be useful in the development of immunostimulatory therapeutics for the treatment of diseases such as cancer and virally mediated disease.
